2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02338960 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

714

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypoactive Sexual Desire Disorder

Interventions

DRUG: Bremelanotide
DRUG: Placebo

Sponsor

Palatin Technologies, Inc

Collaborators

[object Object]